On Wednesday, Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $28.24 which represents a decrease of $-0.14 or -0.49% from the prior close of $28.38. The stock opened at $28.23 and ...

Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn ...

Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...

With a recently acquired FDA nod for its Halozyme Therapeutics-partnered Vyvgat Hytrulo, argenx is looking to take Halozyme’s ...

Gilead Sciences, Inc. has announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six ...

Dr. Reddy's, Hetero, and Mylan partner with Gilead Sciences to manufacture generic lenacapavir for HIV prevention globally.

After unlocking commercial supply and enlisting a manufacturing partner earlier this year, Ferring Pharmaceuticals has ...

If approved, the six manufacturers – Dr Reddy’s Laboratories Limited, Emcure, Eva Pharma, Ferozsons Laboratories Limited, ...

Gilead Sciences signs voluntary licensing agreement with six pharma firms to produce generic lenacapavir: Our Bureau, New Delhi Thursday, October 3, 2024, 11:30 Hrs [IST] US-based ...

Gilead Sciences has announced the signing of voluntary licencing agreements with six generic pharmaceutical manufacturers to ...

Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...

Gilead's licensing agreement for lenacapavir a move to preserve its monopoly, alleges TWN: Our Bureau, New Delhi Thursday, October 3, 2024, 12:20 Hrs [IST] Third World Network (TW ...